These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

402 related items for PubMed ID: 29177870

  • 1. Dosimetric parameters predicting contralateral liver hypertrophy after unilobar radioembolization of hepatocellular carcinoma.
    Palard X, Edeline J, Rolland Y, Le Sourd S, Pracht M, Laffont S, Lenoir L, Boudjema K, Ugen T, Brun V, Mesbah H, Haumont LA, Loyer P, Garin E.
    Eur J Nucl Med Mol Imaging; 2018 Mar; 45(3):392-401. PubMed ID: 29177870
    [Abstract] [Full Text] [Related]

  • 2. Personalized dosimetry with intensification using 90Y-loaded glass microsphere radioembolization induces prolonged overall survival in hepatocellular carcinoma patients with portal vein thrombosis.
    Garin E, Rolland Y, Edeline J, Icard N, Lenoir L, Laffont S, Mesbah H, Breton M, Sulpice L, Boudjema K, Rohou T, Raoul JL, Clement B, Boucher E.
    J Nucl Med; 2015 Mar; 56(3):339-46. PubMed ID: 25678490
    [Abstract] [Full Text] [Related]

  • 3. Dosimetry based on 99mTc-macroaggregated albumin SPECT/CT accurately predicts tumor response and survival in hepatocellular carcinoma patients treated with 90Y-loaded glass microspheres: preliminary results.
    Garin E, Lenoir L, Rolland Y, Edeline J, Mesbah H, Laffont S, Porée P, Clément B, Raoul JL, Boucher E.
    J Nucl Med; 2012 Feb; 53(2):255-63. PubMed ID: 22302962
    [Abstract] [Full Text] [Related]

  • 4. A simple method for estimating dose delivered to hepatocellular carcinoma after yttrium-90 glass-based radioembolization therapy: preliminary results of a proof of concept study.
    Kokabi N, Galt JR, Xing M, Camacho JC, Barron BJ, Schuster DM, Kim HS.
    J Vasc Interv Radiol; 2014 Feb; 25(2):277-87. PubMed ID: 24461133
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Evaluation of factors affecting tumor response and survival in patients with primary and metastatic liver cancer treated with microspheres.
    Demirelli S, Erkilic M, Oner AO, Budak ES, Gunduz S, Ozgur O, Bozcuk H, Sindel HT, Boz A.
    Nucl Med Commun; 2015 Apr; 36(4):340-9. PubMed ID: 25563137
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Radioembolization of hepatocarcinoma with 90Y glass microspheres: treatment optimization using the dose-toxicity relationship.
    Chiesa C, Mira M, Bhoori S, Bormolini G, Maccauro M, Spreafico C, Cascella T, Cavallo A, De Nile MC, Mazzaglia S, Capozza A, Tagliabue G, Brusa A, Marchianò A, Seregni E, Mazzaferro V.
    Eur J Nucl Med Mol Imaging; 2020 Dec; 47(13):3018-3032. PubMed ID: 32451604
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Comparison of absorbed doses to the tumoral and non-tumoral liver in HCC patients undergoing 99mTc-MAA and 90Y-microspheres radioembolization.
    Noipinit N, Sukprakun C, Siricharoen P, Khamwan K.
    Ann Nucl Med; 2024 Mar; 38(3):210-218. PubMed ID: 38142421
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Radioembolization of hepatocarcinoma with (90)Y glass microspheres: development of an individualized treatment planning strategy based on dosimetry and radiobiology.
    Chiesa C, Mira M, Maccauro M, Spreafico C, Romito R, Morosi C, Camerini T, Carrara M, Pellizzari S, Negri A, Aliberti G, Sposito C, Bhoori S, Facciorusso A, Civelli E, Lanocita R, Padovano B, Migliorisi M, De Nile MC, Seregni E, Marchianò A, Crippa F, Mazzaferro V.
    Eur J Nucl Med Mol Imaging; 2015 Oct; 42(11):1718-1738. PubMed ID: 26112387
    [Abstract] [Full Text] [Related]

  • 13. Direct comparison and reproducibility of two segmentation methods for multicompartment dosimetry: round robin study on radioembolization treatment planning in hepatocellular carcinoma.
    Lam M, Garin E, Palard-Novello X, Mahvash A, Kappadath C, Haste P, Tann M, Herrmann K, Barbato F, Geller B, Schaefer N, Denys A, Dreher M, Fowers KD, Gates V, Salem R.
    Eur J Nucl Med Mol Imaging; 2023 Dec; 51(1):245-257. PubMed ID: 37698645
    [Abstract] [Full Text] [Related]

  • 14. Clinical impact of (99m)Tc-MAA SPECT/CT-based dosimetry in the radioembolization of liver malignancies with (90)Y-loaded microspheres.
    Garin E, Rolland Y, Laffont S, Edeline J.
    Eur J Nucl Med Mol Imaging; 2016 Mar; 43(3):559-75. PubMed ID: 26338177
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Planning dosimetry for 90 Y radioembolization with glass microspheres: Evaluating the fidelity of 99m Tc-MAA and partition model predictions.
    Thomas MA, Mahvash A, Abdelsalam M, Kaseb AO, Kappadath SC.
    Med Phys; 2020 Oct; 47(10):5333-5342. PubMed ID: 32790882
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Prognostic utility of 90Y radioembolization dosimetry based on fusion 99mTc-macroaggregated albumin-99mTc-sulfur colloid SPECT.
    Lam MG, Goris ML, Iagaru AH, Mittra ES, Louie JD, Sze DY.
    J Nucl Med; 2013 Dec; 54(12):2055-61. PubMed ID: 24144563
    [Abstract] [Full Text] [Related]

  • 20. High quality imaging and dosimetry for yttrium-90 (90Y) liver radioembolization using a SiPM-based PET/CT scanner.
    Duan H, Khalaf MH, Ferri V, Baratto L, Srinivas SM, Sze DY, Iagaru A.
    Eur J Nucl Med Mol Imaging; 2021 Jul; 48(8):2426-2436. PubMed ID: 33443618
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.